Skip to search formSkip to main contentSkip to account menu

SU 12662

Known as: SU-12662, SU12662 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
SummaryIntroduction Sunitinib is a multikinase inhibitor active in various cancers types including renal cancers and endocrine… 
Highly Cited
2014
Highly Cited
2014
Interpatient variability in the pharmacokinetics (PK) of sunitinib is high. Single nucleotide polymorphisms (SNPs) in PK… 
Highly Cited
2012
Highly Cited
2012
CONTEXT Treatment of refractory adrenocortical carcinoma (ACC) is not established. Animal experiments pointed toward adrenal… 
Review
2012
Review
2012
Highly Cited
2010
Highly Cited
2010
This phase I, open‐label, single‐dose study evaluates the effects of severe renal impairment and end‐stage renal disease (ESRD… 
Highly Cited
2009
Highly Cited
2009
Purpose: Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma and… 
Highly Cited
2007
Highly Cited
2007
PurposeSunitinib, an oral multitargeted tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, FLT3, KIT, and RET, is currently… 
Highly Cited
2006
Highly Cited
2006
The effect of food on the oral bioavailability of sunitinib malate (SU11248, an oral, multi-targeted tyrosine kinase inhibitor…